Everolimus treatment alone prolonged time-to-progression as a surrogate for survival and also CDD866 showed a trend of extension.
← all excerpts
ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments.
1
—
—